Aimin Wu
President @ Sinopharm Capital
Shanghai, China
Aimin Wu is a seed investor at Sinopharm Capital in Shanghai. Mr. Wu holds a bachelor's degree in economics and a master's degree in business administration from Shanghai Jiaotong University. He is currently a PhD candidate at Tsinghua University. He has extensive contacts and more than 20 years of experience in the fields of domestic and international capital market operations, pharmaceuticalindustry strategic development, mergers and acquisitions, business development and financial management. Prior to joining Sinopharm Group, Mr. Wu served as the financial controller of Weiwei (600300) and participated in the A-share listing of Weiwei. After joining Sinopharm Group in 2003, Mr. Wu served as the chief financial officer, deputy general manager and secretary-general of Sinopharm Holding (HK 1099), and served as a director of Concord Pharmaceutical (000028) and Sinopharm (600511). He has played an important role in the restructuring, mergers and acquisitions, listing operations and business operations of Sinopharm Group: responsible for the listing of H-shares of Sinopharm Holding; the share reform and restructuring of Sinopharm and Sinopharm; as the investment manager of Sinopharm, responsible for nearly 20 The investment decision-making, execution, and post-investment business restructuring of the remaining investment acquisition projects.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Stages Aimin Wu invests in
Countries Aimin Wu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Seed / Mar 30, 2022 |
Co-Investors
About Sinopharm Capital
Sinopharm Capital is a private equity arm of China National Pharmaceutical Group Corporation that specializes in medical and healthcare, pharmaceuticals, biotechnology, medical devices, healthcare and medical supply, and services for elderly and persons with disability. It seeks to invest in China. Sinopharm Capital was founded in June 2012 and isbased in Shanghai, China.
Sinopharm Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Aimin Wu
President
|
|||
Fei Jiang
Executive Vice-President
|
|||
|
Shengtao Zhu
Managing Director
|
|||
Xiaoming Yang
Managing Director
|
|||
Yong Kuang
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
FAQ
How do I contact Aimin Wu?
Public channels for Aimin Wu include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Aimin Wu last invest?
The most recent investment recorded for Aimin Wu closed in Mar 2022. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
